DANOY vs UL: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DANOY is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DANOY and UL share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DANOY and UL exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Danone S.A. is a Paris-based packaged food and beverage group with roughly €27 billion in annual sales, sold in more than 120 countries. It runs three businesses. Essential Dairy and Plant-Based is the largest, with brands such as Activia, Danone, Oikos, YoPRO, Silk, Alpro and International Delight coffee creamers. Specialized Nutrition covers infant formula (Aptamil, Nutrilon) and medical nutrition sold under Nutricia to hospitals, pharmacies and patients with specific dietary needs, and it is the group's highest-margin segment. Waters includes Evian, Volvic, Aqua in Indonesia and Mizone in China. Under CEO Antoine de Saint-Affrique, who took over in 2021 after a period of activist pressure and weak growth, Danone has pruned slower brands, exited Russia, and bought into faster-growing health niches: a majority stake in Kate Farms (plant-based tube-feeding and protein shakes), The Akkermansia Company (gut-health supplements) and, completed on September 4, 2026, Huel, the UK complete-nutrition brand bought for roughly €1 billion.

Full DANOY guide

Unilever PLC is one of the world's largest consumer-goods companies, and UL is its NYSE-listed ADR (the London line trades as ULVR, with a further listing in Amsterdam). After the late-2025 demerger of its ice cream arm, Unilever is organized around four business groups: Beauty & Wellbeing (Dove, Vaseline, and premium and wellness brands), Personal Care (deodorants, skin cleansing, and oral care such as Rexona and Lifebuoy), Home Care (laundry and cleaning brands like Persil and Cif), and Foods, also called Nutrition (Knorr, Hellmann's, and cooking products). A large share of turnover now comes from a concentrated set of roughly 30 Power Brands, which the company reports have been growing faster than the overall portfolio. Because it sells low-cost, repeat-purchase essentials, Unilever tends to hold up better than cyclical businesses in downturns, though it is exposed to input-cost inflation, currency swings, and slower volume growth in developed markets.

Full UL guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DANOY drivers: Health-focused portfolio and protein; Specialized Nutrition recovery after the recall.
• UL drivers: Power Brands and premiumization; Growth Action Plan and cost discipline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Product-safety events are the most acute risk for a company that sells infant formula and medical nutrition, as the 2026 recall showed: the ADR fell ~8% on January 21 and ~2.7% more two days later. For UL, the main risk is that a slow-growth staples business trades on the credibility of its turnaround: if the Growth Action Plan does not lift volumes and margins as hoped, the stock can languish.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DANOY if you believe its drivers more; UL if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DANOY and UL guides.

DANOY. At the October 15, 2026 close of ~$13.63 (equal to ~$68 per ordinary share), DANOY trades at roughly 15 to 16 times recurring earnings and around 20 to 21 times reported earnings, which were reduced by ~€725 million of non-recurring charges in 2025 that cut reported net income ~9.7% to ~€1.8 billion even as recurring net income rose ~5% to ~€2.5 billion. That multiple sits at or slightly below large European staples peers such as Nestle and Unilever, after a decline from around $15.5 in late summer. Free cash flow of ~€2.8 billion in 2025 comfortably covered the ~€1.5 billion dividend bill, leaving room for bolt-on deals like Huel. The first-half 2026 recurring EPS of ~€1.92 was up only ~0.9%, reflecting recall costs and currency, so the second half carries most of the year's earnings growth.

UL. At about 17.7x forward earnings and a yield near 3.3%, UL is priced as a steady staple rather than a turnaround that has already worked. The trailing P/E of ~13.4x looks cheaper than it is because 2025 earnings include gains tied to the ice cream separation, so the forward multiple is the cleaner read. Results are reported in euros, so currency moves change the dollar figures, including the dividend, independent of how the business performs.

Headline figures (approximate, October 2026): DANOY shows revenue (ttm) ~€27.4 billion, like-for-like sales growth (h1 2026) ~3.5%, recurring operating margin (h1 2026) ~13.3%, recurring eps (fy 2025) ~€3.80 per share (~€0.76 per ADR); UL shows share price and market cap ~$66.21 per ADR (Oct 16, 2026); market cap ~$143 billion; 52-week range ~$54.75-74.98, revenue (ttm) ~EUR 50.6 billion, after removing ice cream (2024 turnover was ~EUR 60.8 billion), revenue growth (latest quarter, reported) ~+0.5% year on year; Q2 2026 turnover ~EUR 13.05 billion, margins Gross ~47%, operating ~20%, net ~18%.

DANOY and UL are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DANOY and UL exposure against your real portfolio. It is not an investment adviser.